Advanced NGS for Precision Oncology and Targeted Cancer Therapy
NGS (Next-Generation Sequencing) is an advanced genomic technology that enables the simultaneous analysis of multiple cancer-related genes in a single test, supporting precision oncology and personalized treatment planning.
Next-Generation Sequencing (NGS) Testing
Advanced NGS for Precision Oncology and Targeted Cancer Therapy
NGS (Next-Generation Sequencing) is an advanced genomic technology that enables the simultaneous analysis of multiple cancer-related genes in a single test, supporting precision oncology and personalized treatment planning.
500+
Genes Analyzed
24hr
Expert Callback
95%
Clinical Actionability
What is NGS Testing?
NGS full form is Next-Generation Sequencing — an advanced genomic technology used to analyze multiple cancer-related genes simultaneously for precision treatment planning. Unlike single-gene tests, an NGS panel examines hundreds of genes in one NGS test — reducing time, tissue use, and cost while dramatically expanding treatment options.
Instead of testing one gene at a time — a slow, tissue-intensive process — NGS sequencing reads millions of DNA fragments in parallel using technologies like Illumina, SOLiD, and PacBio. The result is a single comprehensive report covering driver mutations, gene fusions, copy number changes, and immunotherapy biomarkers, all from one tumor sample or blood draw. BigOHealth coordinates NGS testing near you, with NGS services available across India through trusted, best-in-class NGS labs.
Quick Facts
500+
Genes Screened
Tissue or Blood
Sample Needed
10–21 Days
Report Time
All Solid Tumors
Cancers Covered
What NGS Testing Can Detect
A single panel screens for every major class of cancer-driving genetic alteration.
SNVs
Single Nucleotide Variants — point mutations in cancer genes
CNVs
Copy Number Variations — gene amplifications and deletions
Fusions
Gene fusions like ALK, RET, ROS1 driving targeted therapy
MSI/TMB
Microsatellite Instability & Tumor Mutational Burden for immunotherapy
Book NGS Testing
Get your comprehensive genomic report in 10–21 days
Confidential • No obligation • Expert callback within 24 hours
How long does your NGS test result take?
Sample Collection
Tumor biopsy (FFPE tissue) or blood draw collected and shipped to lab
DNA Extraction
Laboratory extracts and quality-checks tumor DNA from your sample
Sequencing & Analysis
NGS panel runs; bioinformatics pipeline analyzes millions of DNA reads
Report Generation
Molecular pathologist reviews findings and prepares your comprehensive report
Total turnaround: 10–21 business days from sample collection to final report. Our team calls back within 2 hours of your enquiry to guide you through the process.
NGS Test Cost in India
Transparent NGS sequencing cost across India — pricing depends on panel size and sample type.
Starting Prices
Compare Test Prices
Indicative starting prices for common genomics test options.
What's Included
Targeted Panel
Focused panel for common driver genes
upto ₹35,000
Final NGS sequencing cost in India depends on panel size, lab, and sample type (tissue vs liquid biopsy). Contact us for an exact quote based on your case.
Why NGS Testing Matters
A single NGS panel can change the entire course of treatment — turning a generic chemo plan into a targeted, gene-matched therapy strategy.
70%+
of advanced cancers carry an actionable mutation
40+
targeted drugs matched via NGS biomarkers
3x
more clinical trial options unlocked
Detect actionable mutations
Pinpoints gene alterations matched to approved targeted drugs (EGFR, ALK, BRAF, KRAS G12C and more), replacing guesswork with a precision drug match.
Unlock immunotherapy eligibility
Flags MSI-High and TMB-High status — biomarkers that predict who will actually respond to checkpoint inhibitors like pembrolizumab.
Catch resistance early
When first-line therapy stops working, NGS identifies the resistance mutation driving relapse so the next line of treatment is chosen correctly, not by trial and error.
Sharpen precision oncology decisions
Oncologists get one consolidated genomic profile instead of piecing together scattered single-gene results — faster, more confident treatment calls.
Open access to clinical trials
Many trials require a specific mutation or biomarker for enrollment. NGS is often the only way to qualify for cutting-edge, otherwise unavailable therapies.
Got your report? We'll walk you through it.
What will your NGS test result say?
Your NGS report groups findings into a few categories. None of them alone is a diagnosis — together, they tell your oncologist which treatments are most likely to work.
Actionable Mutations
Gene alterations with approved targeted therapies (e.g., EGFR, ALK, BRCA1/2, KRAS G12C). These give your oncologist a direct, FDA-backed drug match.
MSI Status
Microsatellite Instability — High (MSI-H) tumors respond well to checkpoint inhibitors like pembrolizumab, opening up immunotherapy as an option.
TMB Score
Tumor Mutational Burden — high TMB often predicts immunotherapy response even without a specific actionable mutation.
Copy Number Changes
Gene amplifications (e.g., HER2, MET) or deletions that affect which therapies will or won't work for your tumor.
Gene Fusions
Structural rearrangements like NTRK, RET, ROS1 — rare but highly targetable when found.
Variants of Unknown Significance (VUS)
Mutations detected where clinical significance is still being studied. Not actionable today, but tracked — and may be reclassified as research advances.
Understanding an NGS Report
An NGS report looks technical, but most treatment decisions come from a few key fields: what was tested, sample quality, detected alterations, biomarker scores, and clinical actionability.
Example NGS Report Snapshot
Sample snapshot
Patient / Case
Advanced solid tumor, FFPE tissue sample
Panel Used
Comprehensive 500+ gene cancer panel
Primary Finding
EGFR exon 19 deletion detected
Copy Number
MET amplification not detected
Fusions
ALK, ROS1, RET, NTRK fusions not detected
MSI Status
Microsatellite Stable (MSS)
TMB
6 mutations/Mb, not TMB-high
Interpretation
Actionable targeted therapy option should be reviewed by oncology team
Illustrative example only. Final findings depend on cancer type, sample quality, panel size, and expert review.
Important parameters in an NGS report
Focus first on these fields; the rest add context for your oncology team.
Patient and sample details
Patient identifiers, cancer type, sample source, collection date, and whether the test used tissue, blood, or another specimen.
Sample quality metrics
Tumor content, DNA quantity, DNA quality, sequencing depth, coverage, and whether the sample passed lab quality checks.
Panel scope
The number of genes tested, genomic regions covered, and whether the panel includes DNA, RNA, MSI, TMB, CNV, and fusion analysis.
Detected variants
SNVs, insertions, deletions, and important gene changes such as EGFR, KRAS, BRAF, PIK3CA, BRCA1/2, and TP53 alterations.
Variant allele frequency
The percentage of sequencing reads carrying a variant, helping estimate how strongly the alteration is represented in the tested sample.
Copy number variations
Gene amplifications or deletions such as HER2, MET, MYC, CDKN2A, or PTEN that may influence treatment selection.
View more report parameters
Gene fusions and rearrangements
Structural changes like ALK, ROS1, RET, NTRK, FGFR, or BCR-ABL fusions that can unlock highly specific targeted therapies.
MSI status
Microsatellite instability result, commonly reported as MSI-High or Microsatellite Stable, used to assess immunotherapy eligibility.
Tumor mutational burden
TMB score, usually shown as mutations per megabase, which can help predict checkpoint inhibitor response in selected cancers.
Clinical significance tier
Classification of each finding as actionable, investigational, resistance-related, benign, likely benign, or VUS.
Therapy and trial associations
Approved drugs, off-label options, resistance warnings, and clinical trials that may match the detected molecular profile.
Limitations and recommendations
What the test may miss, whether confirmatory testing is advised, and which findings need oncologist or genetic counselor review.
Second Opinion on Your NGS Report
Received your NGS test results but unsure what the mutations mean for your treatment? Our molecular oncologists in India review your NGS sequencing report, interpret actionable findings, and guide you toward the right targeted therapy or clinical trial.
What our experts review
NGS Results Interpretation
We explain actionable mutations, MSI/TMB status, gene fusions, copy number changes, and VUS findings in plain language so you know what the result means for treatment.
NGS Report Review
Our team checks sample quality, panel coverage, detected variants, clinical significance tiers, therapy associations, and whether any follow-up testing is needed.
NGS Mutation Interpretation
We map reported alterations such as EGFR, ALK, KRAS, BRAF, BRCA1/2, HER2, RET, ROS1, and NTRK to current targeted therapy evidence.
Targeted Therapy Matching
Your mutations are reviewed against approved targeted drugs, off-label evidence, resistance markers, and treatment options available in India.
Clinical Trial Eligibility
We identify whether your NGS findings may qualify you for mutation-matched clinical trials or newer precision oncology options.
Treatment Plan Review
We help your oncology team understand how the NGS report fits with cancer type, stage, previous treatments, current symptoms, and treatment goals.
Why patients trust us
- Reviewed by certified molecular oncologists
- Response within 2 business hours
- 100% confidential — your data stays private
Not sure what your NGS Testing report means?
Benefits of NGS Testing
Every benefit below translates into a more informed, faster, and more personal treatment decision.
Precision Therapy Selection
Match your cancer's exact mutations to approved targeted drugs and immunotherapies
Multi-Gene Testing
Test hundreds of cancer genes in a single panel — faster, cheaper, more comprehensive
Faster Molecular Diagnosis
Get comprehensive molecular profiling in 10–21 days vs months of sequential testing
Personalized Cancer Care
Move beyond one-size-fits-all chemo toward therapies designed for your tumor profile
Clinical Trial Access
Unlock eligibility for cutting-edge trials requiring specific genomic alterations
Resistance Monitoring
Detect resistance mutations early to switch therapies before clinical progression
See exactly which of these benefits apply to your case.
Why You Need a Genetic Counselor After NGS
NGS results are complex. A genetic counselor helps you understand what the mutations mean for you and your family.
Result Interpretation
Translate complex genomic data into clear, actionable insights for your treatment team
Hereditary Risk Assessment
Identify inherited mutations (BRCA1/2, Lynch syndrome) and family implications
Therapy Navigation
Guide you toward targeted therapies and clinical trials based on your mutation profile
Emotional Support
Help process the emotional impact of genetic findings with trained counselors
Other Genomic Tests You May Need
BRCA1/BRCA2 Testing
Hereditary breast & ovarian cancer risk genes
Tumor DNA Sequencing
Somatic mutation profiling for targeted therapy
Hereditary Cancer Panel
150+ gene panel for inherited cancer risk
NGS test in pregnancy
Cancer NGS during pregnancy needs careful coordination between oncology, fetal medicine, and genetics teams. Tissue-based tumor NGS may still be considered when treatment decisions are urgent, while blood-based testing and any fetal implications should be reviewed case by case.
Not sure which test applies to you?
Get a second opinion or consult our multidisciplinary tumor board to confirm the right genomic test for your diagnosis.
NGS Testing Applies Across Cancer Types
Breast Cancer
NGS can identify HER2 amplification, PIK3CA mutations, ESR1 resistance mutations, BRCA1/2 alterations, and other markers that may guide targeted therapy, PARP inhibitor eligibility, or clinical trial options.
Lung Cancer
NGS testing lung cancer cases is especially useful because EGFR, ALK, ROS1, RET, MET, BRAF, NTRK, and KRAS G12C findings can directly change first-line or later-line treatment selection.
Colon Cancer
For colorectal cancer, NGS reviews KRAS, NRAS, BRAF, HER2, NTRK, MSI, and TMB findings to help decide anti-EGFR therapy suitability, immunotherapy options, and trial eligibility.
Ovarian Cancer
NGS can detect BRCA1/2 and homologous recombination repair gene alterations, helping assess PARP inhibitor options and whether germline testing should be considered.
Blood Cancer
In selected blood cancers, NGS can help classify mutations, detect resistance, refine prognosis, and support therapy decisions when combined with hematopathology and flow cytometry.
Brain Tumor
NGS may identify IDH, BRAF, EGFR, TERT, MGMT-related context, NTRK fusions, and other alterations that support diagnosis refinement and targeted therapy discussion.
Prostate Cancer
A prostate cancer NGS panel can look for BRCA1/2, ATM, CHEK2, CDK12, MSI, TMB, and other DNA repair alterations that may guide PARP inhibitors, immunotherapy, or trial options.
Gastric Cancer
NGS can evaluate HER2, MSI, TMB, FGFR2, MET, CLDN18.2-related context, and other molecular markers that may influence targeted therapy and immunotherapy planning.
Frequently Asked Questions
Answers for both first-time patients and those who already have a NGS Testing report in hand.
What is NGS testing for cancer?
NGS (Next-Generation Sequencing) is a genomic test that analyzes hundreds of cancer-related genes simultaneously. It identifies mutations, gene fusions, copy number changes, and biomarkers like MSI and TMB — enabling oncologists to select targeted therapies and immunotherapies matched to your specific tumor.
What is the full form and meaning of NGS?
NGS full form is Next-Generation Sequencing. It refers to a group of modern DNA sequencing technologies (including Illumina, SOLiD, and PacBio platforms) that read millions of DNA fragments in parallel, replacing older one-gene-at-a-time sequencing methods.
Where can I get NGS testing near me in India?
BigOHealth coordinates NGS testing across India, connecting you with accredited NGS labs for sample collection, sequencing, and expert-reviewed reporting — no matter which city you're in.
Who should get NGS testing?
NGS is recommended for patients with advanced or metastatic cancer, those who haven't responded to standard chemotherapy, patients with certain cancer types (lung, breast, colorectal, ovarian), and anyone seeking access to targeted therapies or clinical trials.
What cancers benefit most from NGS testing?
NGS is especially valuable for lung cancer (EGFR, ALK, ROS1), breast cancer (HER2, BRCA), colorectal cancer (KRAS, NRAS, BRAF), ovarian cancer (BRCA), and hematological cancers. However, NGS adds value across almost all solid tumor types.
Molecular profiling through NGS is critical for treatment planning. What does this mean?
Molecular profiling through NGS means studying the genetic changes inside a tumor to understand what is driving the cancer. Instead of choosing treatment only by cancer type or stage, your oncologist can use the NGS report to look for actionable mutations, gene fusions, MSI/TMB status, or resistance markers. These findings can help select targeted therapy, immunotherapy, clinical trial options, or avoid treatments that are unlikely to work.
How long does NGS test result take?
Most NGS reports are delivered in 10–21 business days. The process includes sample collection, DNA extraction, sequencing, bioinformatics analysis, and expert report review by a molecular pathologist.
What is the cost of NGS testing in India?
NGS testing in India typically ranges from ₹35,000 to ₹1,20,000 depending on the panel size (targeted vs. comprehensive), lab, and whether liquid biopsy or tissue biopsy is used. Contact us for current pricing.
What sample is needed for NGS testing?
NGS can be performed on FFPE (formalin-fixed paraffin-embedded) tumor tissue from a biopsy or surgical specimen, or via liquid biopsy using a blood sample to detect circulating tumor DNA (ctDNA).
What is the difference between NGS and liquid biopsy?
Both use DNA sequencing, but liquid biopsy analyzes circulating tumor DNA (ctDNA) from a blood sample, while standard NGS uses tumor tissue. Liquid biopsy is less invasive and useful for monitoring treatment response, but may detect fewer mutations than tissue-based NGS.
Will NGS results help me get into a clinical trial?
Yes. Many precision oncology clinical trials require specific genomic alterations detected by NGS. Having an NGS report significantly expands your eligibility for mutation-matched clinical trials across India and globally.
I already have an NGS report — can you help me understand it?
Yes. If you've already been tested, upload your existing NGS report and our molecular oncology team and genetic counselors will review it with you, explain what each finding means, and help you understand your targeted therapy and clinical trial options — no need to repeat the test.
My NGS report shows no actionable mutations — what now?
A 'no actionable mutation found' result doesn't mean no options remain. It means your specific panel didn't find an FDA-matched target — but your TMB/MSI status, a broader panel, or re-biopsy at progression may still reveal options. A second opinion from a molecular tumor board can clarify next steps.
Can my existing biopsy sample be used for NGS, or do I need a new one?
In most cases, your existing FFPE tumor block from a prior biopsy or surgery can be used for NGS — a new procedure usually isn't required. If tissue is insufficient or too old, a blood-based liquid biopsy is often a non-invasive alternative.
Who reviews and explains my NGS report to me?
Your NGS report is reviewed by a molecular pathologist and interpreted in context of your case by an oncologist or genetic counselor, who will explain the findings, actionable mutations, and treatment implications in clear, patient-friendly terms.
Still have questions about your NGS Testing report or results?
Ready to Move Forward With NGS Testing?
Whichever step you're on — booking your first test, reviewing a report, or unsure what's next — our team is one tap away.
